namitecan

Namitecan is a novel, hydrophilic camptothecin analogue of the 7-oxyiminomethyl series and acts as a potent topoisomerase I inhibitor. It was developed to overcome limitations of earlier camptothecins such as water insolubility and lactone instability. Namitecan stabilizes the DNA-topoisomerase I cleavable complex, leading to persistent DNA damage and cell death in tumor cells. It demonstrates marked cytotoxic potency due to increased intracellular accumulation and favorable subcellular localization. Preclinical studies showed significant antitumor efficacy across various human tumor xenografts—including those resistant to topotecan and irinotecan—with particular activity in squamous cell carcinomas, bladder cancer, and endometrial carcinoma. The drug has an acceptable toxicity profile with neutropenia as the dose-limiting effect. Clinical development is ongoing for solid tumors[1][4][5][6][7].

Brand names

namitecan

Other names

372105-27-6Namitecan [INN]UNII-X34Z8N66T3UNII-X-34Z8N66T3UNII-X 34Z8N66T3